Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Subscribe To Our Newsletter & Stay Updated
